Allon Therapeutics Inc.
TSX : NPC

Allon Therapeutics Inc.

March 17, 2009 09:15 ET

Allon CEO to Present at Cowen and Company Investment Conference

VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 17, 2009) - Allon Therapeutics Inc. (TSX:NPC) has announced that President and CEO Gordon McCauley has been invited to present the Company's progress on its 2009 corporate and clinical milestones today at 3:10 p.m. EDT in Boston at the 29th Annual Cowen and Company Health Care Conference.

McCauley's presentation will outline that the Company's existing cash resources are sufficient to fund its business into 2011 and meet its 2009 milestones.

The Allon presentation is being webcast live at: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=NPC.TO&item_id=2124178 and will be available for recorded viewing at http://www.allontherapeutics.com/events_webcasts.html one hour after its conclusion.

About Allon

Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for major neurodegenerative conditions. Allon's drug davunetide intranasal (AL-108) has demonstrated human efficacy in amnestic mild cognitive impairment, a precursor to Alzheimer's disease. Allon has Phase II human efficacy programs pursuing large underserved markets: Alzheimer's disease, frontotemporal dementia, and schizophrenia-related cognitive impairment. The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuro Protection Company™) and based in Vancouver. For additional information please visit the Company's website: www.allontherapeutics.com

Forward Looking Statements

Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. While forward-looking statements represent management's outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, Allon's early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which Allon may eventually develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and Allon's dependence on collaborative partners and contract research organizations. These factors can be reviewed in Allon's public filings at www.SEDAR.com and should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements and Allon disclaims any obligation to update or announce changes in any such factors except in its periodic filings.

Contact Information